CRISPR-Armed Phage Therapy Cured a Superbug Infection in a Human for the First Time

What Happened: Rapid Wound Healing and 89% Mass Reduction

The phage therapy was administered intravenously, topically on the wounds, and injected directly into the mass, alongside continued antibiotics, ascorbic acid, and bethanechol . The response was both rapid and sustained:

The case was published in Clinical Infectious Diseases on August 11, 2026 .

How It Works: Direct Killing and Biofilm Disruption

CRISPR-armed phages act through two likely synergistic mechanisms:

1. Direct bacterial killing: The phages inject their genetic material into E. coli cells. Inside, the CRISPR-Cas system targets and cleaves specific bacterial DNA sequences, causing rapid bacterial death .
2. Biofilm disruption: SNIPR Biome's prior research showed its CRISPR phages can kill bacteria within thick biofilms. By breaking up these protective layers that antibiotics cannot penetrate, the phages likely made the concurrent antibiotics more effective — though this synergy was not formally tested in this case .

Important Caveats

• Concomitant therapy confounds the results: The patient started a new combination of more powerful antibiotics and other drugs 11 days before the phages were given. It is unclear how much of the improvement came from the phages alone versus a synergistic effect with the antibiotics .
• Single case, no control: This is an n=1 compassionate-use report, not a controlled trial. Generalizability is unknown .
• Disease specificity: Malakoplakia is a rare intracellular E. coli condition. Whether the same approach works in sepsis, urinary tract infections, or other E. coli infections is unconfirmed.
• Manufacturing complexity: Engineering phages, confirming specificity, and producing clinical-grade material remains expensive and time-consuming .

What Comes Next for CRISPR-Armed Phage Therapy

• Phase 1b/2a trial (recruitment complete): SNIPR Biome is testing an oral formulation of SNIPR001 in people with blood cancer to prevent E. coli bloodstream infections .
• Phase 2a expansion: The company is also developing SNIPR001 for active E. coli infections beyond prophylaxis .
• Earlier Phase 1 data: A randomized, placebo-controlled Phase 1 trial in 36 healthy volunteers (published in The Lancet Microbe, March 2026) showed SNIPR001 was safe, well-tolerated, and remained restricted to the GI tract without disrupting the normal gut microbiome .
• Broader platform potential: SNIPR Biome's engineered CRISPR medicine platform could be adapted to target other multidrug-resistant pathogens .

The Bottom Line

This case provides the first-in-human proof-of-concept that CRISPR-armed bacteriophage therapy can safely achieve dramatic clinical improvement in a patient with a multidrug-resistant E. coli infection where all antibiotics had failed. Rigorous controlled trials are now the critical next step.